SAN DIEGO and SUZHOU, China, Nov 23 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced two poster presentations featuring clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116, at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021.
The conference abstracts are expected to be published on the ESMO-IO website on Thursday, December 2, 2021 and posters available on Monday, December 6 in advance of the hybrid meeting being held virtually and in Geneva, Switzerland from December 8 to 11, 2021.
